文献速递临床试验与 GCP基础与转化研究

CRYSTALLBrain:非创伤性蛛网膜下腔出血患者的晶体液选择与神经功能结局——多中心随机双盲临床试验研究方案

CRYSTALLBrain: crystalloid fluid choice and neurological outcome in patients with non-traumatic subarachnoid haemorrhage-a study protocol for a multi-centre randomised double-blind clinical trial.
PubMed 文献 · Trials · 2025-10-17

CRYSTALLBrain是一项多中心随机双盲临床试验,拟将非创伤性蛛网膜下腔出血患者按1:1随机分配至生理盐水组或林格乳酸盐组,盲法研究液体仅用于复苏和维持直至ICU/IMC出院或最长14天(以先发生者为准)。主要终点为临床相关血管痉挛的发生,关键次要结局包括死亡率、血管痉挛的严重程度与治疗及90天神经功能结局。

要点

  • 非创伤性蛛网膜下腔出血患者按1:1随机接受生理盐水或林格乳酸盐,双盲设计。
  • 盲法研究液体仅用于复苏和维持,直至ICU/IMC出院或最长14天(以先发生者为准)。
  • 主要终点为临床相关血管痉挛的发生,关键次要结局包括死亡率及90天神经功能结局。

核心结论

  • 该随机对照试验旨在评估生理盐水较林格乳酸盐是否减少蛛网膜下腔出血患者临床相关血管痉挛。

研究设计与样本

  • 多中心随机双盲临床试验,非创伤性蛛网膜下腔出血患者按1:1随机分配至生理盐水组或林格乳酸盐组。
  • 盲法研究液体仅用于复苏和维持,直至ICU/IMC出院或最长14天,以先发生者为准。
  • 血管痉挛管理与蛛网膜下腔出血患者的一般管理按临床标准诊疗进行。

关键数值与推荐

  • 主要终点为临床相关血管痉挛的发生。
  • 关键次要结局包括死亡率、血管痉挛的严重程度与治疗及90天神经功能结局。
  • 试验注册于ClinicalTrials.gov(注册日期2021年6月18日)及瑞士国家临床试验门户SNCTP000004575。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vasospasms are common in patients presenting with non-traumatic subarachnoid haemorrhage (SAH) and are the main contributor to long-term disability or death in these patients. The key immediate management of vasospasms is the improvement of brain perfusion by the administration of intravenous fluid and vasopressors if needed. Yet, there is no clear recommendation regarding the choice of fluid in this particular patient population. Data suggests a survival benefit using normal saline in patients with TBI; however, its impact on outcomes in patients with SAH is lacking. Thus, the aim of this study is to evaluate whether the use of normal saline reduces clinically relevant vasospasms compared to Ringer's lactate in patients with SAH. METHODS: Patients presenting with non-traumatic SAH will be randomised 1:1 to normal saline or Ringer's lactate group. Blinded study fluid will be used exclusively for resuscitation and maintenance until ICU/IMC discharge or a maximum of 14 days, whichever occurs first. Management of vasospasms and general management of the SAH patient will be according to the clinic standard of care. Primary endpoint is the occurrence of clinically relevant vasospasms. Key secondary outcomes include mortality, severity and treatment of vasospasms, and neurological outcomes at 90 days. DISCUSSION: The proposed randomised controlled trial offers a safe, non-invasive way to gain insights about crystalloid fluid choice in SAH patients, with potential to improve outcomes in this critically ill patient group. This study could establish a new gold standard in fluid therapy for neuro-critical care. TRIAL REGISTRATION: The trial is registered on ClinicalTrials.gov (date of registration 18 June 2021) and on the Swiss National Clinical Trials Portal, SNCTP000004575.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Messmer AS, Pitteloud M, Quintard H, et al. CRYSTALLBrain: crystalloid fluid choice and neurological outcome in patients with non-traumatic subarachnoid haemorrhage-a study protocol for a multi-centre randomised double-blind clinical trial. Trials. 2025. PMID: 41107997. doi:10.1186/s13063-025-09099-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。